Sorafenib is an oral multikinase inhibitor that inhibits tumor growth and proliferation by interfering with several receptor tyrosine kinases involved in the pathogenesis and perpetuation of ...

As with sunitinib, sorafenib is a substrate for CYP isoenzymes in the liver and is extensively metabolized during first-pass metabolism. Sorafenib is primarily metabolized by CYP3A4 and undergoes ...